Microglial MHC class II is dispensable for experimental autoimmune encephalomyelitis and cuprizone-induced...

Area of Science:

• Neuroimmunology
• Cellular Immunology
• Central Nervous System (CNS) Research

Background:

• Microglia, the resident immune cells of the CNS, are crucial for immune defense and inflammation.
• Microglial major histocompatibility complex class II (MHCII) expression is induced upon activation, but its functional significance in CNS autoimmunity and demyelination is debated.
• It remains unclear whether microglial MHCII facilitates antigen presentation for T-cell responses or influences microglial signaling.

Purpose of the Study:

• To investigate the role of microglial MHCII in CNS autoimmune disorders and demyelination.
• To determine if microglial antigen presentation is essential for the development of experimental autoimmune encephalomyelitis (EAE).
• To explore potential antigen presentation-independent functions of microglial MHCII in demyelination models.

Main Methods:

• Generation of mice with microglia-specific MHCII deficiency using a CX3CR1^CreER-based system.
• Assessment of EAE development, including onset, progression, and severity, in mutant and wild-type mice.
• Evaluation of chemically induced demyelination using cuprizone, analyzing white matter alterations, microglial proliferation, and gene expression.

Main Results:

• Microglial MHCII deficiency did not alter the onset, progression, or severity of EAE, indicating antigen presentation by microglia is not critical for this autoimmune disease.
• Absence of microglial MHCII did not affect the extent of white matter damage or repair in the cuprizone-induced demyelination model.
• Microglial proliferation and gene expression related to de- and remyelination were also unaffected by the lack of microglial MHCII.

Conclusions:

• Microglial antigen presentation via MHCII is dispensable for the establishment and progression of EAE.
• Microglial MHCII does not appear to have critical roles in antigen presentation-independent functions during chemically induced demyelination.
• These findings suggest that targeting microglial MHCII may not be a viable strategy for treating CNS autoimmune or demyelinating diseases.